StockData
Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc. (RANI) stock

RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3043% above fair value
$0.56+0.02 (+3.54%)

Close on Nov 17, 2026Market cap $77.98MP/E –Yield –

Rani Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Rani Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$20.29M. For fiscal 2025 it was -$18.71M. The highest annual figure on record is -$14.96M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$18.71M–
FY2024Dec 31, 2024-$35.50M–
FY2023Dec 31, 2023-$51.24M–
FY2022Dec 31, 2022-$46.52M–
FY2021Dec 31, 2021-$32.25M–
FY2020Dec 31, 2020-$14.96M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.03M–
Q1 FY2026Mar 31, 2026-$6.50M–
Q4 FY2025Dec 31, 2025$294.00K–
Q3 FY2025Sep 30, 2025-$5.06M–
Q2 FY2025Jun 30, 2025-$5.80M–
Q1 FY2025Mar 31, 2025-$8.15M–
Q4 FY2024Dec 31, 2024-$8.66M–
Q3 FY2024Sep 30, 2024-$8.41M–
Q2 FY2024Jun 30, 2024-$9.03M–
Q1 FY2024Mar 31, 2024-$9.40M–
Q4 FY2023Dec 31, 2023-$12.48M–
Q3 FY2023Sep 30, 2023-$14.30M–
Q2 FY2023Jun 30, 2023-$12.30M–
Q1 FY2023Mar 31, 2023-$12.15M–
Q4 FY2022Dec 31, 2022-$14.63M–
Q3 FY2022Sep 30, 2022-$12.20M–
Q2 FY2022Jun 30, 2022-$10.33M–
Q1 FY2022Mar 31, 2022-$9.36M–
Q4 FY2021Dec 31, 2021-$11.45M–
Q3 FY2021Sep 30, 2021-$11.12M-1759.7%
Q2 FY2021Jun 30, 2021-$5.63M–
Q1 FY2021Mar 31, 2021-$4.05M–
Q4 FY2020Dec 31, 2020-$6.70M–
Q3 FY2020Sep 30, 2020$670.00K–

More Rani Therapeutics figures

See a number that looks wrong?